Development and validation of a machine learning-based predictive model for early outcomes following combined suction-assisted lipectomy and lymphovenous anastomosis in breast cancer-related lymphedema: a retrospective cohort study - Summary - MDSpire
Advertisement
Development and validation of a machine learning-based predictive model for early outcomes following combined suction-assisted lipectomy and lymphovenous anastomosis in breast cancer-related lymphedema: a retrospective cohort study
To develop a predictive framework for early postoperative outcomes in patients with breast cancer-related lymphedema undergoing combined suction-assisted lipectomy and lymphovenous anastomosis, thereby improving patient management.
Key Findings:
300 patients were enrolled, with a satisfactory outcome rate of 72.3% at 6 months.
Three stable predictors identified: postoperative excess limb volume, disease duration, and disease severity grade, which are crucial for clinical decision-making.
SVM model showed optimal performance with AUC of 0.891, sensitivity of 90.8%, and specificity of 62.5%.
Interpretation:
The SVM model effectively predicts early postoperative outcomes, enabling risk stratification and identification of patients needing closer monitoring, which can directly influence clinical management.
Limitations:
Retrospective design may introduce bias.
Single-center study limits generalizability.
Potential confounding variables may not have been accounted for in the analysis.
Conclusion:
The SVM model, integrated with SHAP analysis and a web-based tool, facilitates early risk stratification for patients post-surgery, aiding in the development of standardized rehabilitation protocols and suggesting areas for future research.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
